Our reader has substantial savings but wonders if focusing on income is holding him back. Dave Baxter finds out ...

The FTSE 100 hit 9,200 as mining stocks took up the baton and ran on Friday morning following a third straight record close on Wall Street. Glencore, Antofagasta and Anglo American all rose 2-3 per ...

One company worth examining is Equinix (US:EQIX), a California-based multinational that specialises in internet connectivity and co-location centres. It essentially offers space within data centres, ...

As results season winds down, Dan Jones and team discuss a property group’s results, alternative ways to find bargain stocks and Novo Nordisk vs Eli Lilly ...

Investors Chronicle provides share tips, stock market data and analysis, as well as beginners’ guides on how to invest in shares and the stock market. We cover most UK companies’ financial results, ...

Investors Chronicle provides share tips, stock market data and analysis, as well as beginners’ guides on how to invest in shares and the stock market. We cover most UK companies’ financial results, ...

CPI inflation rose more than expected in the last reading, to 3.6 per cent in June. The MPC now thinks price growth will peak at 4 per cent in September, driven higher by food prices.

Copper miner Antofagasta (ANTO) revved up its interim profits through higher gold and copper production, resulting in a mid-year payout twice that of last year. The cash profit was $2.2bn (£1.6bn), ...

Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Investors Chronicle provides share tips, stock market data and analysis, as well as beginners’ guides on how to invest in shares and the stock market. We cover most UK companies’ financial results, ...

With an excellent record of investing in quality growth companies, the fund bets big on the continent’s return to form ...

RTW Biotech Opportunities (RTW:138¢) is a specialist healthcare investor in innovative biotech and medtech companies. The closed-end fund has been successful, generating an annualised 10.1 per cent ...